Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TFEB | P19484 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974888 | 1.00 | HPGD (0.51) | HPGDMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4978650 | 0.93 | LMNA (0.47) | HPGDMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4978659 | 0.93 | LMNA (0.47) | HPGDMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4973644 | 0.92 | LMNA (0.44) | HPGDMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4973639 | 0.92 | LMNA (0.44) | HPGDMAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4978489 | 0.90 | HSP90AB1 (0.51) | HPGDMAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL4976337 | 0.90 | HSP90AB1 (0.51) | HPGDMAPTSMN1; SMN2KDM4EHSP90AB1 | |
| SCHEMBL4976348 | 0.90 | HSP90AB1 (0.51) | HPGDMAPTSMN1; SMN2KDM4EHSP90AB1 | |
| SCHEMBL4978474 | 0.90 | HSP90AB1 (0.51) | HPGDMAPTSMN1; SMN2RAB9AKDM4E | |
| SCHEMBL4979716 | 0.89 | HSP90AB1 (0.42) | MAPTHSP90AB1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | HPGD 159/4885MAPT 2301/4885SMN1; SMN2 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.